Poseltinib (Synonyms: HM71224; LY3337641) |
Catalog No.GC60298 |
Poseltinib, un inhibiteur de la tyrosine kinase de Bruton (BTK) actif, sélectif et irréversible par voie orale (IC50 = 1,95 nM), avec une sélectivité de 0,3, 2,3 et 2,4 fois pour BTK par rapport À BMX, TEC et TXK, respectivement.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1353552-97-2
Sample solution is provided at 25 µL, 10mM.
Poseltinib, an orally active, selective and irreversible Bruton's tyrosine kinase (BTK) inhibitor (IC50 =1.95 nM), with 0.3, 2.3 and 2.4-fold selectivity for BTK over BMX, TEC and TXK, respectively. Poseltinib can covalently bind to the active site (cysteine 481 residue) of BTK, and reveales potent inhibition of B cell receptor (BCR), Fc receptor (FcR), Toll-like receptor (TLR) mediated signaling[1].
[1]. Kim YY, et al. HM71224, a selective Bruton's tyrosine kinase inhibitor, attenuates the development of murine lupus. Arthritis Res Ther. 2017 Sep 26;19(1):211.
Average Rating: 5
(Based on Reviews and 38 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *